Whalesbook
Cohance Lifesciences Faces Steep Revenue Slump Amid Regulatory Hurdles
Cohance Lifesciences has reported a significant downturn in its financial performance for the third quarter and first nine months of fiscal year 2026. The company's consolidated revenue for Q3 FY26 fell by a steep 19.5% year-on-year to ₹545 Crore, while for the nine-month period, revenue declined by 6.7% to ₹1,650 Crore. This performance marks a concerning trend, contrasting with previous growth phases often seen in the pharmaceutical contract development and manufacturing (CDMO) sector.
The Core Issues: Regulatory Woes and Destocking
The primary drivers behind this sharp decline are multifaceted. A substantial destocking impact from two large commercial products accounted for approximately ₹260 Crore in revenue loss. Compounding these commercial challenges, the company's Nacharam formulation facility received a Warning Letter following an Official Action Indicated (OAI) status from regulatory authorities. This has led to a deferral of about ₹55 Crore in shipments and underscores significant operational and compliance hurdles. Management acknowledged these disruptions as key factors impacting EBITDA, which saw a considerable year-on-year drop in the 9-month period, though specific Q3 EBITDA figures were provided with margin percentages.
Revised Outlook and Future Strategy
In light of these pressing issues, Cohance Lifesciences has drastically revised its outlook for the full fiscal year 2026. The company now expects an early-to-mid double-digit revenue decline. This revised forecast paints a challenging immediate picture for investors, necessitating a close watch on the company's remedial actions.
However, management expressed optimism for fiscal year 2027, projecting it to be a year of recovery and growth. This growth is anticipated to be fueled by the recovery of its development pipeline and a strengthened performance in the 'API Plus' segment. The company remains committed to its ambitious long-term target of achieving USD 1 billion in sales by fiscal year 2030. The strategic focus remains on enhancing its Contract Research, Development, and Manufacturing Organization (CRDMO) platform, with significant investments planned in quality, regulatory compliance, and complex chemistry capabilities. Deepening ties with large global innovators is also a key pillar of their forward-looking strategy.
Financial Health and Cash Flow
Despite the revenue pressures and operational disruptions, the company described its balance sheet as "sound". Furthermore, Cohance Lifesciences managed to generate a positive free cash flow of ₹175 Crore during the first nine months of FY26, with capital expenditure standing at ₹161 Crore. This demonstrates an ability to generate cash even amidst significant operational volatility, which is a crucial positive sign for financial stability.
Investor Risks and Governance
Beyond the immediate financial performance, investors face several critical risks. The Nacharam facility's Warning Letter is a significant regulatory concern, potentially impacting future export capabilities to regulated markets. While remediation actions are underway and non-US market production has resumed, the full impact and resolution timeline remain crucial to monitor. The pharma CDMO segment itself saw a notable 27% YoY decline in Q3 FY26 revenue (though this figure excludes the destocking impact, which was 7% growth excluding it). Subsidiary performance has also been muted, attributed to lower project renewals and a challenging biotech funding environment. Customer-driven delays in product scale-ups and launches, coupled with broader biotech funding constraints, add further layers of operational risk.
Peer Comparison
The pharmaceutical contract manufacturing sector in India is competitive. Companies like Syngene International and Laurus Labs also operate in the CDMO and API space. Syngene, for instance, has a strong focus on R&D services and a robust order book, often showcasing consistent growth. Laurus Labs, while facing its own challenges, has been expanding its CDMO offerings. Cohance's current situation, particularly the regulatory issue at its formulation site, sets it apart negatively from peers who may not be facing such immediate compliance crises. The market generally favors companies with strong regulatory compliance and consistent execution, areas where Cohance is currently under scrutiny. While the long-term target of USD 1 billion is ambitious, achieving it will depend heavily on resolving the current operational and regulatory challenges swiftly and demonstrating sustained recovery.